{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Foncologypodcast.simplecast.com%2Fepisodes%2Fasco-2026-updates-in-mbc-hJYcxLFr","width":444,"version":"1.0","type":"rich","title":"ASCO 2026 Updates in Metastatic Breast Cancer","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/165defb8-f7d7-44fe-a7eb-a59f2c35d334/38415b01-066d-46e4-ad4a-c0656d3ee2f3/cropped_1790086686520.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/8d1fdabf-f53f-49ed-82ba-904af7dd0585\" height=\"200\" width=\"100%\" title=\"ASCO 2026 Updates in Metastatic Breast Cancer\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"In this podcast, experts review practice-informing data presented at the ASCO 2026 annual conference that may reshape treatment decisions in metastatic breast cancer. The discussion examines ctDNA-guided treatment adaptation for emergent ESR1 mutations in HR-positive/HER2-negative disease, emerging endocrine-based precision strategies targeting ER and PI3K/AKT signaling, and first-line TROP2-directed antibody-drug conjugates in metastatic triple-negative breast cancer. The experts place the SERENA-6, ELEVATE, PIKALO-1, ASCENT-04, ASCENT-03, and TROPION-Breast02 findings in clinical context and how the results, including biomarker testing, immunotherapy eligibility, sequencing, safety, and the maturity of the evidence are influencing their clinical practice."}